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Abstract
Background: While many of the phenotypic differences between human and chimpanzee may result from changes in gene
regulation, only a handful of functionally important regulatory differences are currently known. As a first step towards
identifying transcriptional pathways that have been remodeled in the human lineage, we focused on a transcription factor,
FOXO1a, which we had previously found to be up-regulated in the human liver compared to that of three other primate
species. We concentrated on this gene because of its known role in the regulation of metabolism and in longevity.
Methodology: Using a combination of expression profiling following siRNA knockdown and chromatin immunoprecip-
itation in a human liver cell line, we identified eight novel direct transcriptional targets of FOXO1a. This set includes the gene
for thioredoxin-interacting protein (TXNIP), the expression of which is directly repressed by FOXO1a. The thioredoxin-
interacting protein is known to inhibit the reducing activity of thioredoxin (TRX), thereby hindering the cellular response to
oxidative stress and affecting life span.
Conclusions: Our results provide an explanation for the repeated observations that differences in the regulation of FOXO
transcription factors affect longevity. Moreover, we found that TXNIP is down-regulated in human compared to chimpanzee,
consistent with the up-regulation of its direct repressor FOXO1a in humans, and with differences in longevity between the
two species.
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Introduction
In addition to substitutions at the protein level, changes in gene
regulation are likely to underlie many phenotypes of interest,
including human-specific adaptations and diseases [1–8]. But while
many human-specific adaptations in gene copy number and protein
sequence have been documented, only a few differences in gene
regulation between humans and other apes are known [9–11].
In order to identify human-specific changes in regulatory
pathways, we focused on a transcription factor, the Forkhead box
O1A transcription factor (FOXO1a), which we had previously
found to be significantly up-regulated in human livers compared to
that of three non-human primates [12]. We concentrated on this
gene because of its pivotal role in the regulation of metabolism and
in longevity (reviewed by [13]), a phenotype that differs markedly
between humans and other primates [14].
The FOXO transcription factors are key targets of the insulin/
IGF signaling pathway (reviewed by [15]). Humans and mice have
four functional FOXO genes (21, 3, 4, and 6), while flies (dFOXO)
and worms (DAF-16) have one [13]. Changes in the regulation of
FOXO transcription factors affect the median and maximum life
span in C. elegans [16,17] and D. melanogaster [18] and, in rodents,
the inhibition of the insuling/IGF-1 signaling pathway in mice
[19,20] and rats [21] results in increased longevity. It has further
been shown that inhibition of FOXO transcription factors in
worms, flies, and mammalian cellular systems results in differences
in expression of a large number of genes, and in particular, leads to
decreased expression of enzymes that protect against or repair
oxidative damage and, as a result, to higher sensitivity to oxidative
stress [22–24]. Since oxidative stress is thought to be an important
determinant of the rate of aging (reviewed by [25]), at least one
mechanism by which changes in the regulation of FOXO affect life
span may be through the regulation of genes involved in
protection from reactive oxygen species (ROS) [22,23,26].
These functions of FOXO in the insulin signaling pathway and
the response to ROS, and its role in promoting longevity, appear
to be evolutionarily conserved: When the expression level of FOXO
is perturbed, the corresponding changes in gene expression
patterns as well as the resulting phenotypes are similar across
distantly related species (reviewed by [26]). However, while dosage
manipulations of FOXO result in expression level changes at a
large number of genes, to date, only a few have been shown to be
directly regulated by FOXO transcription factors [27,28]. In
particular, although FOXO has been shown to regulate the
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[27,28], the direct transcriptional targets through which FOXO
mediates the cellular response to oxidative stress and life span
remained elusive.
Results
Identifying the direct transcriptional targets of FOXO1a
As a first step of our analysis of FOXO1a regulatory pathways, we
validated the original microarray observation of FOXO1a mRNA
expression differences between humans and other primates by using
quantitative RT-PCR on human and chimpanzee liver RNA
samples (Figure S1). We also confirmed that the expression of
FOXO1a at the protein level is elevated in the human liver compared
to that of chimpanzee (Figure S1). Available genomic sequences
(http://genome.ucsc.edu/)indicatethatthehumanandchimpanzee
FOXO1a proteins only differ at one residue (at position 62), which is
not within the forkhead box DNA binding domain or any known
protein-protein interaction domain, and is not known to be a target
of any regulatory post-translational modification. This observation
suggests that the human and chimpanzee FOXO1a orthologs have
similar biochemical properties - including DNA binding - and that
their regulation at the protein level (e.g., their localization) may be
similar. Thus, the observed difference in FOXO1a gene expression
levels between human and chimpanzee likely results in differences in
the regulation of FOXO1a transcriptional targets between the two
species [29].
To identify direct FOXO1a transcriptional targets in the human
liver, we used a combination of approaches. First, we examined
changes in gene expression levels following a knockdown of FOXO1a
in human liver cell lines by using siRNA transfection (see Materials
and Methods). The knockdown of FOXO1a resulted in a significant
(FDR,0.05) change in the expression of 490 genes (Figure 1 and
Table S1). Only a subset of the 490 differentially expressed genes are
likely to be direct targets of FOXO1a, since many gene expression
changes likely result from regulatory network perturbations (e.g., the
genes may be regulated by the direct targets of FOXO1a, or by genes
that are farther downstream in the cascade. In addition, the
knockdown of a transcription factor may affect the cellular
environment in ways that may trigger larger changes in the gene
expression profiles, not directly related to the regulatory effects of the
perturbed transcription factor).
To hone in on the subset of direct targets, we then searched for
the known binding motif of FOXO1a in the putative promoters of
the 490 differentially expressed genes. Our analysis was limited to
the ,1 kb segments upstream of known transcription start sites
(see Materials and Methods for details), and hence was far from
exhaustive. Nonetheless, 21 genes whose expression levels were
significantly elevated or reduced by the knockdown were found to
contain FOXO1a binding motif in their promoters. These 21 genes
are likely direct transcriptional targets of FOXO1a (Table 1).
One concern is that computational searches for transcription
factor binding sites are known to have a high rate of false positives
[30]. We therefore validated the in silico analysis using Chromatin
ImmunoPrecipitation (ChIP) with a FOXO1a antibody, followed
by PCR amplification of the 21 promoter regions predicted to
contain a FOXO1a binding site (see Materials and Methods). The
promoters for eight (38%) of the 21 genes were found to be
enriched in PCR amplifications following the ChIP with FOXO1a
antibody, compared to the control experiment (Figure 2). In
summary, by intersecting the results of expression profiling
following a FOXO1a knockdown, computational analyses and
PCR amplification of ChIP enriched promoter regions, we
identified eight novel direct transcriptional targets of FOXO1a.
Since FOXO1a expression levels are elevated in humans
compared to chimpanzees, we hypothesized that a subset of the
eight direct transcriptional targets of FOXO1a would be differen-
tially expressed between the species. Specifically, based on the
Figure 1. FOXO1a knockdown in human HepG2/C3A liver cells. A. FOXO1a Western blots are shown for one of the three siRNA biological
replicates, indicating that the level of the FOXO1a protein is dramatically reduced. B. Zoom into a picture of a cDNA microarray co-hybridization of
RNA from one biological replicate of cells treated with FOXO1a siRNA (Cy3 - green) and RNA from untreated cells (Cy5 - red). The circle marks the
cDNA probe for FOXO1a. As can be seen, FOXO1a mRNA levels are reduced following the knockdown. We note that this microarray result was
validated by using quantitative RT-PCR. C. A volcano plot for results of the comparison of gene expression profiles following FOXO1a knockdown to
the control siRNA treatment. The eight confirmed direct transcriptional target of FOXO1a are indicated by arrows. In the plot, all P-values smaller than
10
29 are plotted as P=10
210 (P-values ranged from 1 to 10
243).
doi:10.1371/journal.pone.0001670.g001
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Figure 2), we predicted that the expression levels of the genes
ABCB1, EiFG4, RARS,a n dTAF11 would be elevated in humans
while the genes B4GALT3, PRDX4, PRG4,a n dTXNIP would show
reduced expression levels in humans compared to chimpanzees. To
test this hypothesis, we measured the expression levels of these eight
genes in RNA samples from the livers of six human and six
chimpanzee individuals, using quantitative RT-PCRs (see Materials
and Methods).Ascan be seeninfigure3,fourofthe eightgeneswere
found nottobesignificantlydifferentiallyexpressedbetween humans
and chimpanzees (at the 5% level), while for one gene, PRDX4,t h e
difference in expression between the species was not consistent with
our prediction. A likely explanation is that compensatory mutations
in humans offset the effect of elevated FOXO1a levels on the
expression of these five genes, as have been observed previously in
fruit flies [31,32] and inferred from a comparison of human and
mouse regulatory sequences [33]. We conclude that changes in
FOXO1a expression levels cannot explain the observed inter-species
gene expression profiles for these five genes.
In contrast, our predictions were met for three genes: We found
a significant inter-species difference in gene expression for the
Table 1. Potential direct transcriptional targets of FOXO1a
identified in-silico
Gene name
Position of FOXO1a binding site
relative to the TSS
SEPP1 2283
KIAA0763 2410
TXNIP 2126
KNG 2246
FOXO1a 2353
ABCB1 2612
GLUD2 2346
EIF4G2 2989
RARS 2399
CHD1 +63
B4GALT3 2767
TAF11 2205
CLN3 2459
PDIR 2733
CREG 2345
PRDX4 2478
HKE2 220
ACO1 2814
TST 2978
G6PC 2987
PRG4 2837
doi:10.1371/journal.pone.0001670.t001
Figure 2. FOXO1a ChIP results. Gel electrophoresis pictures of PCR
amplifications following FOXO1a ChIP, for the putative promoters of the
eight direct transcriptional targets of FOXO1a.
doi:10.1371/journal.pone.0001670.g002
Figure 3. Quantitative RT-PCR results. Mean fold differences (y-axis) and standard errors for six biological replicates (different individuals) are
given for either the human (dark bars) or chimpanzee (clear bars) liver RNA samples. For each gene (x-axis), results were standardized based on the
species with the lower expression level (set to 1). Stars indicate gene that are differentially expressed between human and chimpanzee at either
P,0.1 (*) or P,0.05 (**) (see text).
doi:10.1371/journal.pone.0001670.g003
FOXO1a Transcriptional Targets
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marginally significant, consistent difference (P=0.09) for RARS
(Figure 3). For these three genes, it is likely that elevated level of
FOXO1a gene expression in humans compared to chimpanzees
resulted in an inter-species difference in transcript levels.
FOXO1a regulates the oxidative stress response
pathways
Of the three genes, relatively little is known about the function
of TAF11 (TATA binding protein-associated factor 11) and RARS
(arginyl-tRNA synthetase). In contrast, TXNIP (Thioredoxin
interacting protein, also termed vitamin D3 up-regulated protein
1–VDUP1, and thioredoxin-binding protein 2 – TBP2) has been
studied extensively. In particular, TXNIP has been shown to
inhibit the reducing activity of thioredoxin (TRX) through direct
protein-protein interaction [34–36]. Because TRX plays a critical
role in regulating the cellular response to oxidative stress [37–39],
the presence of high levels of its inhibitor, TXNIP, increases the
vulnerability of the cell to ROS [35]. Thus, our results point to a
direct link between changes in the regulation of FOXO1a and the
cellular response to oxidative stress.
The role of TRX in the ROS detoxification pathway is well
understood [37–39], and the protein-protein interaction between
TXNIP and TRX has been clearly demonstrated [34–36]. We
wanted to provide similarly strong evidence that binding of FOXO1a
to the promoter of TXNIP indeed affects TXNIP expression level in
humans. To do so, we used site directed mutagenesis to mutate the
FOXO1a binding site in the promoter of TXNIP. We then examined
the difference in TXNIP promoter activity with and without the
binding site for FOXO1a, by using reporter gene assays in human
liver cell lines (see Material and Methods). As can be seen in figure 4,
TXNIP promoter activity is significantly (P,10
25) elevated when the
binding site for FOXO1a is mutated, consistent with our observation
that FOXO1a is a direct repressor of TXNIP.
Discussion
By using a combination of genomic approaches, we found that
TXNIP is a directregulatory target of FOXO1a. The effectof changes
in the regulation of TXNIP and TRX on the response to oxidative
stressandlifespanwasfoundtobeconservedacrosswormsandmice
[37,38], and more speculatively, in flies [34] and pigs [40]. Although
increased response to oxidative stress may not be the only
mechanism through which changes in FOXO regulation affect life
span [27], our findings provide an explanation for the repeated
observations that elevated levels of FOXO transcription factors
enhance the response to ROS and increase longevity in a number of
model organisms. As a direct transcriptional repressor of TXNIP,
elevated expression levels of FOXO result in lower levels of TXNIP,
which in turn results in increased TRX-reducing activity [34,35],
improved cellular response to oxidative stress [38], and ultimately
increased life span [27,38].
Our observations that the FOXO1a expression level is elevated in
human livers compared to chimpanzee livers and consistently, that
TXNIP expression levels are lower, provide one of very few well
documented examplesof differences inregulatory pathwaysbetween
the species and raise an intriguing hypothesis, namely that the
cellular response to ROS is increased in humans compared to
chimpanzee. While currently we cannot exclude the possibility that
compensatory changes offset the effect of FOXO1a and TXNIP,w e
note that the binding site for FOXO1a in the promoter of TXNIP is
highly conserved across species, and in particular, is identical in
humans and chimpanzees (Figure S2). Thus, our findings are
consistent with the hypothesis that increased resistance to ROS
contributes to greater life span in humans [41], and is particularly
intriguing given the well-documented difference in life expectancy
and maximum life span between humans and chimpanzees [14,42].
Functional studies of oxidative stress response are needed in order to
directly test this hypothesis.
Materials and Methods
Quantitative RT-PCR
We performed quantitative RT-PCR in order to: (i) Validate the
original microarray observation of differences in FOXO1a gene
expression between humans and chimpanzees, (ii) confirm the
FOXO1a knockdown in HepG2/C3A liver cells (see below), and
(iii) test for inter-species differences expression of the eight FOXO1a
direct transcriptional targets (see below). Total RNA was extracted
from liver cell lines using the RNA Mini kit (Qiagen, Valencia,
CA), and from human and chimpanzee liver tissue samples using
Trizol (Invitrogen, Carlsbad, CA). In all cases, we synthesized first-
strand cDNA using a poly-T oligonucleotide and the Superscript
enzyme (Invitrogen, Carlsbad, CA). The first strand cDNA was
then used as template for quantitative RT-PCR with the
Figure 4. Reporter gene assays with TXNIP promoter. Mean fold activity compared to the control empty vector (y-axis) and standard errors for
five replicates are given for either the original TXNIP promoter (dark bars) or the mutated version (empty bars).
doi:10.1371/journal.pone.0001670.g004
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all reactions, PCR primers and probes were designed in sequences
that are identical between human and chimpanzee (based on their
available genomic sequence (http://genome.ucsc.edu/)). In each
reaction, the final concentrations of the primers and the probe
were 200 nM and 100 nM, respectively. The cycling conditions
were as follows: initial denaturation at 94uC for 2 min, following
by 40 cycles of denaturation at 94uC for 15 sec and annealing/
extension at 60uC for 1 min. b2Actin was used as control for gene
expression analyses. Inter-species differences in gene expression
were evaluated using a t-test.
Western Blots
We performed Western blots in order to: (i) Confirm that
FOXO1a protein expression level is elevated in human compared
to chimpanzees, and (ii) confirm the FOXO1a knockdown in
HepG2/C3A liver cells (see below). In both cases (cell lines or
tissue samples), proteins were extracted in RIPA buffer (Tris-HCl:
50 mM, pH 7.4 NP-40: 1%; Na-deoxycholate: 0.25%; NaCl:
150 mM; EDTA: 1 mM) and proteases inhibitors (PMSF: 1 mM,
Aprotinin, leupeptin, pepstatin: 1 mg/ml each). The protein
extracts subjected to electrophoresis using a MiniGel apparatus
and then transferred onto the Immuno-Blot PVDF Membrane
(Biorad Laboratories, Hercules, CA). The antibody against
FOXO1a was purchased from Cell Signaling Technology (Danvers,
MA) and visualized with the ECL plus Western Blotting Detection
System (Amersham Biosciences, Piscataway, NJ).
siRNA knockdown and microarray hybridizations
In order to knockdown FOXO1a in HepG2/C3A human liver
cells, we transfected the cells with two different siRNAs (Ambion,
Austin, TX), which target different region of the gene. As a control,
we transected the cells with Ambion SilencerH Negative Control
siRNA. Each transfection was performed in three biological
replicates. Total RNA was extracted from each biological replicate,
as well as from untreated cells, using the RNA Mini kit (Qiagen,
Valencia, CA). First strand cDNA was synthesized using a T7-poly-
T oligo and the superscript enzyme (Invitrogen, Carisbad, CA).
Second strand cDNA was synthesized using DNA Pol I enzyme
(Invitrogen, Carisbad, CA). The double strand cDNA was subjected
to linear amplification using MEGAscript (Ambion, Austin, TX),
and RNA was purified using the RNeasy kit (Qiagen, Valencia, CA).
For each microarray hybridization, 4 mg of amplified RNA were
used for amino-allele labeling (BD Bioscience, Palo Alto, CA) with
either Cy3 (for the specific or control siRNA treatment) or Cy5 (for
the untreated cells) dyes (Amersham, Buckinghamshire, UK).
Labeled samples were co-hybridized to the multi-species cDNA
array described previously [12,43] according to a reference design
where the RNA from untreated cells serve as the reference and using
two technical replicates for each biological sample (for a total of 12
hybridizations). Hybridization and washes were carried out as
described in reference (1).
Analysis of microarray hybridizations
The 12 cDNA arrays were scanned using a GenePix Axon
scanner and data were extracted with GenePix 6 (Molecular
Devices, Sunnyvale CA), resulting in Cy5 and Cy3 foreground and
background intensities (using the morph background estimation
procedure). Subsequent analysis was performed using the R
computing environment (http://www.r-project.org). Background
corrected Cy5 and Cy3 intensities were produced using the
‘normexp’ method with an offset of 50, implemented in the limma
software package [44], and within-array lowess normalization was
performed using all probes.
The microarray that we used includes orthologous probes from
humans, and three other closely related primates [12]. We have
previously shown that differential expression between samples
from the same species can be estimated using probes from a closely
related species [45]. Hence, we were able to combine data from all
probes on the array (i.e., including those for non-human species).
The expression log-ratios of the Cy5 to Cy3 intensity (M) for each
gene were analyzed using the following linear mixed model where
we have suppressed the individual gene labels:
Mtrip~mtzppzatrizetrip : ð0:1Þ
Here mt is the fixed effect for the treatment t (either FOXO1a or
control siRNA treatment) and the term pp is the fixed effect for the
probe where p=h,c,o or r (for human, chimpanzee, orangutan or
rhesus macaque) is the probe species. atri is a random effect for
technical replicate i within each biological replicate r, which is
assumed to be uncorrelated with mean zero and variance s
2
a. etrip is
the residual error term with variance s
2, assumed to be uncorrelated
with mean zero. The random effect for technical replicates was
handled by pooling the variances across replicates using the method
of reference [44]. Tests of significance were conducted using
empirical Bayesmoderated t-testswhichensurestable inferenceeven
with small sample size [46]. Differentially expressed genes were
identified at a false discovery rate [47] of 5%.
Identifying FOXO1a binding sites
Our goal was to identify FOXO1a binding sites in the promoters of
the 490 genes whose expression levels were significantly different
followingFOXO1aknockdown(seeabove).Todoso,wefirstusedthe
database of transcription start sites (DBTSS, http://dbtss.hgc.jp/) to
identify an empirically validated transcription start site (TSS) for 287
of the 490 differentially expressed genes. We then defined putative
promoters as the sequences ranging from 1000 bp upstream to
200 bp downstream of the TSS. To search for the signature of the
FOXO1a binding site in these 287 putative promoters, we used
MATCH [48], together with FOXO1a positional weight matrices
from the TRANSFAC database (http://www.gene-regulation.
com/).WeidentifiedFOXO1abindingsitesintheputativepromoters
of 21 genes (table 1). For three of these genes (SEPP1, B4GALT,a n d
CREG) we found two putative FOXO1a binding sites inthepromoter.
In subsequent analysis of these promoters (see below), we only tested
one site for each promoter - the one with highest similarity to the
FOXO1a consensus binding site (assessed by p-values output by
MATCH [48]).
Chromatin Immunoprecipitation
In order to validate the computational prediction of FOXO1a
binding sites, we used Chromatin Immunoprecipitation (ChIP),
following the EZ ChIP protocol (Upstate Millipore, Billerica, MA).
Human liver HepG2/C3A cells were crosslinked in 1% formalde-
hyde, then lysed at a concentration of 10
7 cells/ml in 1% SDS,
10 mM EDTA, 50 mM Tris, pH 8.1. Subsequently, DNA was
sheared by sonication in a Bioruptor (Diagenode) to a range of 300–
1000 bp. We used 10
6 cell equivalents of lysate for one immuno-
precipitation and incubated over night at 4uCw i t h2mg of either the
antibody against FOXO1a or with the rabbit IgG as negative control
(both from Santa Cruz Biotechnology, Santa Cruz, CA). After
precipitation, the chromatin was first de-crosslinked and then
purified by using the PCR product purification kit (Qiagen,
Valencia, CA). Enrichment of specific promoter regions was
evaluated by PCR amplification using 1/50 of the immunoprecip-
itated chromatin as template, with the GoTaq Flexi DNA
FOXO1a Transcriptional Targets
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Peltier Thermal Cycler (Biorad Laboratories).
Reporter gene assays
We designed PCR primers to amplify a product from ,100 bp
downstream of the putative TSS of TXNIP to ,900 bp upstream
of it. We ligated the PCR products into the Luciferase reporter
gene vector pGL4.14 (Promega), and cloned them in JM109
competent cells. We then used the Quikchange II site-directed
mutagenesis kit (Stratagene) to introduce individual nucleotide
changes to the promoter, which removed the binding site for
FOXO1a while maintaining the exact length of the construct.
Specifically, we mutated the FOXO1a binding site ‘AAACA’ into
‘TAAGA’ – a sequence that is not known to be an exact motif of
any transcription factor based on the TRANSFC database, which
currently (August 2007) includes 443 human binding motifs (the
binding motifs of transcription factors ZF5, CTF, and NF1 are
similar to the mutated sequence, but none of these transcription
factors is expressed in the liver based on the Novartis gene
expression atlas (http://expression.gnf.org/cgi-bin/index.cgi)).
Weusedtouch-downPCRtoamplifyandthensequence(usingan
ABI3730automated sequencer)theinsertfromindividualcoloniesin
order to confirm that no Taq-generated errors were incorporated in
either the original or mutated promoters. Once the sequence of the
insert from individual colonies was confirmed, we proceeded by
extracting the plasmid and using it in transfections of human liver
HEP cells by using Lipofectamine 2000 (Invitrogen) with 200 ng of
each plasmid. The HEP cells were also transfected with 20 ng of the
Renilla vector pGL4.73 (Promega). The co-transfection allows us to
normalize across experiments for transfection efficiency. Luciferase
and Renillaactivitywere measured24 hoursaftertransfection,using
Dual-glo Luciferase kit (Promega) in a Veritas 96-well plate
luminometer (Turner Biosystems).
Reporter gene study design and analysis
The Luciferase activity of each construct was measured using
five replicates (independent transfections). In addition, we
measured Luciferase activity for an empty (i.e., with no promoter)
pGL4.14 vector, in five replicates, in order to estimate background
Luciferase transcription levels. For each replicate, we normalized
Luciferase by Renilla luminescence values in order to control for
transfection efficiency. We then standardized the normalized
luminescence values by the background activity (of the empty
vector). We used a t-test to test for difference in activity between
the original and the mutated promoter. The choice of a t-test is
appropriate as we can not reject the hypothesis that the data is
normally distributed (using Shapiro-Wilk test for normality).
Unfortunately, since chimpanzee liver cell lines are not available,
we could not perform the reciprocal experiment.
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